{"url_path":"/sec/vygr/8-k/2026-06-01/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1640266/0001104659-26-068591-index.html","accession_number":"0001104659-26-068591","cik":"0001640266","ticker":"VYGR","issuer_name":"Voyager Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1640266/0001104659-26-068591-index.html","primary_entity_key":"0001640266","primary_entity_name":"Voyager Therapeutics, Inc."},"word_count":311,"has_tables":true,"body_markdown":"false\n0001640266\n\n0001640266\n\n2026-06-01\n2026-06-01\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of The Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of Earliest Event\nReported): **June 1, 2026**\n\n \n\n \n\n \n\n**Voyager\nTherapeutics, Inc.**\n\n(Exact name of\nregistrant as specified in its charter)\n\n \n\n \n\n \n\n**Delaware**\n \n**001-37625**\n \n**46-3003182**\n\n(State\nor other jurisdiction\n\nof incorporation)\n \n(Commission\n\nFile Number)\n \n(I.R.S.\nEmployer\n\nIdentification No.)\n\n \n\n**75 Hayden Avenue**\n\n**Lexington****,\nMassachusetts**\n \n**02421**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\nRegistrant’s telephone number,\nincluding area code **(857****) 259-5340**\n\n \n\n**Not Applicable**\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨ \nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨ \nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨ \nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨ Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n \n\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which\n\nregistered\n\nCommon\nStock, $0.001 par value\nVYGR\nNasdaq\nGlobal Select Market\n\n \n\nIndicate by check mark whether the registrant is\nan emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}